taselisib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Taselisib is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA).   Wikipedia

Chemistry

  • SMILES: CC(C)n1nc(C)nc1c2cn3CCOc4cc(ccc4c3n2)c5cnn(c5)C(C)(C)C(=O)N
  • InChIKey: BEUQXVWXFDOSAQ-UHFFFAOYSA-N
  • Mol. Mass: 460.54
  • ALogP: 3.17
  • ChEMBL Molecule:
    taselisib  
More Chemistry

Pharmacology

Alternative names

2-(3-(2-(1-isopropyl-3-methyl-1h-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide | gdc-0032 | rg-7604 | taselisib

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (27)


 

Bile Duct Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioma (Phase 2)

Healthy Volunteers (Phase 1)

Kidney Neoplasms (Phase 2)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2/Phase 3)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Proteus Syndrome (Phase 1/Phase 2)

Skin Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Thyroid Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue